Activator protein-1 (AP-1) signalling in human atherosclerosis: Results of a systematic evaluation and intervention study

Clinical Science

Volumn 122, Issue 9, 2012, Pages 421-428

  Meijer, C Arnoud ^a   Le Haen, Pum A A ^a   Van Dijk, Rogier A ^a   Hira, Mitsuhisa ^a   Hamming, Jaap F ^a   Van Bockel, J Hajo ^a   Lindeman, Jan H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Activator protein 1 (AP 1); Atherosclerosis; Clinical trial; Doxycycline; Inflammation

Indexed keywords

PROTEIN C JUN; TRANSCRIPTION FACTOR AP 1; AUTACOID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DOXYCYCLINE; STRESS ACTIVATED PROTEIN KINASE;

AORTA WALL; ARTICLE; ATHEROSCLEROSIS; HUMAN; IMMUNOHISTOCHEMISTRY; INTERVENTION STUDY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; AGED; AORTA; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL;

AGED; AORTA; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROSS-OVER STUDIES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DOXYCYCLINE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION MEDIATORS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1;

EID: 84857748122     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20110234     Document Type: Article

References (38)

1. Ford, I., Murray, H., Packard, C. J., Shepherd, J., Macfarlane, P.W. and Cobbe, S. M. (2007) Long-term follow-up of the West of Scotland Coronary Prevention Study. N. Engl. J. Med. 357, 1477-1486
2. De Caterina, R., Massaro, M., Scoditti, E. and Annunziata Carluccio, M. (2010) Pharmacological modulation of vascular inflammation in atherothrombosis. Ann. N.Y. Acad. Sci. 1207, 23-31
3. Wang, J., An, F. S., Zhang, W., Gong, L., Wei, S. J., Qin, W. D., Wang, X. P., Zhao, Y. X., Zhang, Y., Zhang, C. and Zhang, M. X. (2011) Inhibition of c-Jun N-terminal kinase attenuates low shear stress-induced atherogenesis in apolipoprotein E-deficient mice. Mol. Med. 17, 990-999
4. Muslin, A. J. (2008) MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin. Sci. 115, 203-218
5. Osto, E., Matter, C. M., Kouroedov, A., Malinski, T., Bachschmid, M., Camici, G. G., Kilic, U., Stallmach, T., Boren, J., Iliceto, S. et al. (2008) c-Jun N-terminal kinase 2 deficiency protects against hypercholesterolemia-induced endothelial dysfunction and oxidative stress. Circulation 118, 2073-2080
6. Manning, M. W., Cassis, L. A. and Daugherty, A. (2003) Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler. Thromb. Vasc. Biol. 23, 483-488
7. Kim, H. S., Luo, L., Pflugfelder, S. C. and Li, D. Q. (2005) Doxycycline inhibits TGF-β1-induced MMP-9 via Smad and MAPK pathways in human corneal epithelial cells. Invest. Ophthalmol. Visual Sci. 46, 840-848
8. Lindeman, J. H., Abdul-Hussien, H., van Bockel, J. H., Wolterbeek, R. and Kleemann, R. (2009) Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm: doxycycline selectively depletes aortic wall neutrophils and cytotoxic T cells. Circulation 119, 2209-2216
9. Virmani, R., Kolodgie, F. D., Burke, A. P., Farb, A. and Schwartz, S. M. (2000) Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 20, 1262-1275
10. Keeton, M. R., Curriden, S. A., van Zonneveld, A. J. and Loskutoff, D. J. (1991) Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor β. J. Biol. Chem 266, 23048-23052
11. Lindeman, J. H. N., Pijl, H., Toet, K., Eilers, P. H. C., van Ramshorst, B. and Buijs, M. M. (2007) Human visceral adipose tissue and the plasminogen activator inhibitor type 1. Int. J. Obes. 31, 1671-1679
12. van Dijk, R. A., Virmani, R., von der Thüsen, J. H., Schaapherder, A. F. and Lindeman, J. H. (2010) The natural history of aortic atherosclerosis: a systematic histopathological evaluation of the peri-renal region. Atherosclerosis 210, 100-106
13. Criqui, M. H., Langer, R. D., Fronek, A., Feigelson, H. S., Klauber, M. R., McCann, T. J. and Browner, D. (1992) Mortality over a period of 10 years in patients with peripheral arterial disease. N. Engl. J. Med. 326, 381-386
14. Gokce, N., Keaney, Jr, J. F., Hunter, L. M., Watkins, M. T., Nedeljkovic, Z. S., Menzoian, J. O. and Vita, J. A. (2003) Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J. Am. Coll. Cardiol. 41, 1769-1775
15. Akamatsu, D., Sato, A., Goto, H., Watanabe, T., Hashimoto, M., Shimizu, T., Sugawara, H., Sato, H., Nakano, Y., Miura, T. et al. (2010) Nitroglycerin-mediated vasodilation of the brachial artery may predict long-term cardiovascular events irrespective of the presence of atherosclerotic disease. J. Atheroscler. Thromb. 17, 1266-1274
16. Hukshorn, C. J., Lindeman, J. H., Toet, K. H., Saris,W. H., Eilers, P. H., Westerterp-Plantenga, M. S. and Kooistra, T. (2004) Leptin and the proinflammatory state associated with human obesity. J. Clin. Endocrinol. Metab. 89, 1773-1778
17. Cheetham, C., O'Driscoll, G., Stanton, K., Taylor, R. and Green, D. (2001) Losartan, an angiotensin type I receptor antagonist, improves conduit vessel endothelial function in Type II diabetes. Clin. Sci. 100, 13-17
18. Metzler, B., Hu, Y., Dietrich, H. and Xu, Q. (2000) Increased expression and activation of stress-activated protein kinases/c-Jun NH2-terminal protein kinases in atherosclerotic lesions coincide with p53. Am. J. Pathol. 165, 1875-1886
19. Rivard, A., Principe, N. and Andrés, V. (2000) Age-dependent increase in c-fos activity and cyclin A expression in vascular smooth muscle cells. A potential link between aging, smooth muscle cell proliferation and atherosclerosis. Cardiovasc. Res. 45, 1026-1034
20. Chen, Y. and Currie, R. W. (2005) Heat shock treatment suppresses angiotensin II-induced SP-1 and AP-1 and stimulates Oct-1 DNA-binding activity in heart. Inflamm. Res. 54, 338-343
21. Chen, F., Eriksson, P., Hansson, G. K., Herzfeld, I., Klein, M., Hansson, L. O. and Valen, G. (2005) Expression of matrix metalloproteinase 9 and its regulators in the unstable coronary atherosclerotic plaque. Int. J. Mol. Med. 15, 57-65
22. Hansson, G. K. and Hermansson, A. (2011) The immune system in atherosclerosis. Nat. Immunol. 12, 204-212
23. Brevetti, G., Silvestro, A., Di Giacomo, S., Bucur, R., Di Donato, A., Schiano, V. and Scopacasa, F. (2003) Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden. J. Vasc. Surg. 38, 374-379
24. Arcaro, G., Zenere, B. M., Saggiani, F., Zenti, M. G., Monauni, T., Lechi, A., Muggeo, M. and Bonadonna, R. C. (1999) ACE inhibitors improve endothelial function in type 1 diabetic patients with normal arterial pressure and microalbuminuria. Diabetes Care 22, 1536-1542
25. Taneva, E., Borucki, K., Wiens, L., Makarova, R., Schmidt-Lucke, C., Luley, C. andWestphal, S. (2006) Early effects on endothelial function of atorvastatin 40 mg twice daily and its withdrawal. Am. J. Cardiol. 97, 1002-1006
26. Barth, J. D. (2002) An update on carotid ultrasound measurements of intima-media thickness. Am. J. Cardiol. 89, 32B-39B
27. Faulx, M. D., Wright, A. T. and Hoit, B. D. (2003) Detection of endothelial dysfunction with brachial artery ultrasound scanning. Am. Heart J. 145, 943-951
28. Ryan, M. E., Ramamurthy, S. and Golub, L. M. (1996) Matrix metalloproteinases and their inhibition in periodontal treatment. Curr. Opin. Periodontol. 3, 85-96
29. Bendeck, M. P., Conte, M., Zhang, M., Nili, N., Strauss, B. H. and Farwell, S. M. (2002) Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. Am. J. Pathol. 160, 1089-1095
30. Soory, M. (2007) Periodontal diseases and rheumatoid arthritis: a coincident model for therapeutic intervention? Curr. Drug Metab. 8, 750-757
31. Sapadin, A. N. and Fleischmajer, R. (2006) Tetracyclines: nonantibiotic properties and their clinical implications. J. Am. Acad. Dermatol. 54, 258-265
32. Caton, J. and Ryan, M. E. (2011) Clinical studies on the management of periodontal diseases utilizing subantimicrobial dose doxycycline (SDD). Pharmacol. Res. 63, 114-120
33. McKeage, K. and Deeks, E. D. (2010) Doxycycline 40 mg capsules (30 mg immediate-release/10 mg delayed-release beads): anti-inflammatory dose in rosacea. Am. J. Clin. Dermatol. 11, 217-222
34. Smith, K. and Leyden, J. J. (2005) Safety of doxycycline and minocycline: a systematic review. Clin. Ther. 27, 1329-1342
35. Axisa, B., Loftus, I. M., Naylor, A. R., Goodall, S., Jones, L., Bell, P. R. and Thompson, M. M. (2002) Prospective, randomized, double-blind trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques. Stroke 33, 2858-2864
36. Lindeman, J. H., Abdul-Hussien, H., Schaapherder, A. F., Van Bockel, J. H., Von der Thüsen, J. H., Roelen, D. L. and Kleemann, R. (2008) Enhanced expression and activation of pro-inflammatory transcription factors distinguish aneurysmal from atherosclerotic aorta: IL-6- and IL-8-dominated inflammatory responses prevail in the human aneurysm. Clin. Sci. 114, 687-697
37. Joseph, A., Ackerman, D., Talley, J. D., Johnstone, J. and Kupersmith, J. (1993) Manifestations of coronary atherosclerosis in young trauma victims. An autopsy study. J. Am. Coll. Cardiol. 22, 459-467
38. Kardara, M., Papazafiropoulou, A., Katsakiori, P., Petropoulos, C. and Jelastopulu, E. (2006) Protective effect of doxycycline use on coronary artery disease? J. Infect. 52, 243-246